TY - JOUR
T1 - Pros and cons of bariatric surgery in adolescents
AU - Mingrone, Geltrude
PY - 2017
Y1 - 2017
N2 - The global prevalence of overweight and obesity
combined escalated by about 47% in children and
adolescents between 1980 and 2013.1
About 30%
of adolescents in the USA and 22–25% in Europe are
overweight or obese.2
Overweight and obese adolescents show a high
prevalence of cardiometabolic risk factors, including high
levels of cholesterol, triglycerides, blood pressure, fasting
blood glucose, and HbA1c, as well as hypertension, nonalcoholic
fatty liver disease, and metabolic syndrome.3,4
Most cases of diabetes in children and young adults are
now type 2 diabetes rather than type 1, and the rate of
progression of macrovascular complications in young
people with type 2 diabetes is higher than in those with
type 1 diabetes.4
Unfortunately, hypocaloric diet, lifestyle modifi cation,
and medical treatment do not have much of an
eff ect in adolescent populations because of poor
adherence. Additionally, intensive behavioural weight
loss interventions that are eff ective at reducing
BMI in adolescents who are overweight or obese
have diminished eff ectiveness for those with severe
obesity.5
In a randomised trial,6
orlistat (120 mg daily)
in combination with a hypocaloric diet, behavioural
therapy, and physical exercise led to modest weight loss
at 1 year (at least a 5% decrease in BMI was reported
in 26·5% of patients in the orlistat group vs 15·7% in
the placebo group; p=0·005), with mild-to-moderate
gastrointestinal adverse events occurring in 9–50% of
patients. Furthermore, the 3-month reduction in BMI
obtained with exenatide is modest (2·7%, 95% CI −5·02
to −0·37; p=0·025) and associated with side-eff ects such
as nausea (62%), abdominal pain (15%), diarrhoea (8%),
and vomiting (31%).7
AB - The global prevalence of overweight and obesity
combined escalated by about 47% in children and
adolescents between 1980 and 2013.1
About 30%
of adolescents in the USA and 22–25% in Europe are
overweight or obese.2
Overweight and obese adolescents show a high
prevalence of cardiometabolic risk factors, including high
levels of cholesterol, triglycerides, blood pressure, fasting
blood glucose, and HbA1c, as well as hypertension, nonalcoholic
fatty liver disease, and metabolic syndrome.3,4
Most cases of diabetes in children and young adults are
now type 2 diabetes rather than type 1, and the rate of
progression of macrovascular complications in young
people with type 2 diabetes is higher than in those with
type 1 diabetes.4
Unfortunately, hypocaloric diet, lifestyle modifi cation,
and medical treatment do not have much of an
eff ect in adolescent populations because of poor
adherence. Additionally, intensive behavioural weight
loss interventions that are eff ective at reducing
BMI in adolescents who are overweight or obese
have diminished eff ectiveness for those with severe
obesity.5
In a randomised trial,6
orlistat (120 mg daily)
in combination with a hypocaloric diet, behavioural
therapy, and physical exercise led to modest weight loss
at 1 year (at least a 5% decrease in BMI was reported
in 26·5% of patients in the orlistat group vs 15·7% in
the placebo group; p=0·005), with mild-to-moderate
gastrointestinal adverse events occurring in 9–50% of
patients. Furthermore, the 3-month reduction in BMI
obtained with exenatide is modest (2·7%, 95% CI −5·02
to −0·37; p=0·025) and associated with side-eff ects such
as nausea (62%), abdominal pain (15%), diarrhoea (8%),
and vomiting (31%).7
KW - Endocrinology
KW - Endocrinology, Diabetes and Metabolism
KW - Internal Medicine
KW - Endocrinology
KW - Endocrinology, Diabetes and Metabolism
KW - Internal Medicine
UR - http://hdl.handle.net/10807/100547
UR - http://www.journals.elsevier.com/the-lancet-diabetes-and-endocrinology
U2 - 10.1016/S2213-8587(16)30425-9
DO - 10.1016/S2213-8587(16)30425-9
M3 - Article
SN - 2213-8587
VL - 5
SP - 152
EP - 154
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
ER -